Trevi Therapeutics, Inc.
16.64USD
-0.1800 (-1.07%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -21 | -15 | -10 | -14 | -14 | -11 | -12 | -14 |
| Net Income | -18 | -13 | -8 | -12 | -12 | -10 | -11 | -13 |
| EPS (Diluted) | $-0.11 | $-0.09 | $-0.06 | $-0.08 | $-0.09 | $-0.09 | $-0.11 | $-0.13 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)